Global Gastro-Esophageal Reflux Disease Clinical Trial Pipeline Highlights 2019 – Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, Company – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Gastro-Esophageal Reflux Disease Clinical Trial Pipeline Highlights –
2019” report has been added to ResearchAndMarkets.com’s
offering.

Gastro-Esophageal Reflux Disease Pipeline Highlights – 2019, provides
most up-to-date information on key pipeline products in the global
Gastro-Esophageal Reflux Disease market. It covers emerging therapies
for Gastro-Esophageal Reflux Disease in active clinical development
stages including early and late stage clinical trials. The pipeline data
presented in this report helps executives for tracking competition,
identifying partners, evaluating opportunities, formulating business
development strategies, and executing in-licensing and out-licensing
deals.

Clinical Trial Stages:

The report provides Gastro-Esophageal Reflux Disease pipeline products
by clinical trial stages including both early and late stage development
– phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Gastro-Esophageal Reflux Disease pipeline products
by their dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Gastro-Esophageal Reflux Disease pipeline products
by the company.

Short-term Launch Highlights:

Find out which Gastro-Esophageal Reflux Disease pipeline products will
be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Gastro-Esophageal Reflux Disease Pipeline by Stages

2. Gastro-Esophageal Reflux Disease Phase 3 Clinical Trial Insights

3. Gastro-Esophageal Reflux Disease Phase 2 Clinical Trial Insights

4. Gastro-Esophageal Reflux Disease Phase 1 Clinical Trial Insights

5. Gastro-Esophageal Reflux Disease Preclinical Research Insights

6. Gastro-Esophageal Reflux Disease Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/5nmawl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Gastrointestinal
Drugs